Prostate Cancer Foundation 2026 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer REQUEST FOR LETTERS OF INTENT IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 2-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of investigators from academic and community institutions that will directly contribute to improved outcomes for patients with prostate cancer with lethal potential. These awards will be funded depending on the level of innovation and transformative potential in applications received. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world. TACTICAL Awards provide $5 - $10 Million U.S.D. per award over 3–5 years.

ANNOUNCEMENT: RFA for 2026 PCF TACTICAL Award Letters Of Intent for large-scale transformative team science research projects to target mechanisms of lethal #ProstateCancer.

LOI DEADLINE: March 16, 2026

View RFA: res.cloudinary.com/pcf/images/v...
View LOI form: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2026 Young Investigator Awards REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers. Since 2007, PCF has awarded 469 PCF Young Investigator Awards in 16 countries, making it one of the most prodigious, productive, competitive and prestigious early career awards in cancer research. We are pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply. The mission of PCF is to fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer.

ANNOUNCEMENT: RFA for 2026 Prostate Cancer Foundation Young Investigator Award Applications, for early career investigators dedicated to transformative research to end #ProstateCancer.

DEADLINE: Feb 23, 2026 Apply at: pcf.smartsimple.com

View the RFA: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2026 PCF Challenge Awards For Prostate Cancer with Lethal Potential REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Applications for PCF Challenge Awards for Team Science investigations of prostate cancer with lethal potential. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world. PCF Challenge Awards: • Should be composed of at least 3 investigators capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research. • May be assembled from one institution, or several institutions. • Must embed at least one young investigator as an integral contributor to the team. To qualify as a young investigator, this team member must have a doctoral-level degree and be within six years of completion of their terminal degree or subsequent mentored academic or clinical training program including postdoctoral or clinical fellowships.

ANNOUNCEMENT: RFA for 2026 Prostate Cancer Foundation team science Challenge Award Applications, to support investigations of #ProstateCancer with lethal potential.

DEADLINE: March 16, 2026

Apply at: pcf.smartsimple.com (portal opens on Jan 12)

View the RFA: res.cloudinary.com/pcf/images/v...

Manager, Scientific Programs and Communications Job at Prostate Cancer Foundation in Santa Monica, California Apply for PROSTATE CANCER FOUNDATION Manager, Scientific Programs and Communications Job in Santa Monica, California

Come join our science team at PCF! www.cancercareers.org/jobs/4860599...

FDA grants regular approval to rucaparib On December 17, 2025, the Food and Drug Administration (FDA) approved rucaparib (Rubraca, pharmaand GmbH).

New FDA approval for patients with advanced #ProstateCancer!
Rucaparib (Rubraca) now approved for metastatic castration-resistant prostate cancer with a deleterious BRCA mutation & previously treated with an androgen receptor-directed therapy (pre-chemo).
www.fda.gov/drugs/resour...

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting Introduction The 12th Annual 2025 Coffey—Holden Prostate Cancer Academy (CHPCA) Meeting, “Deciphering Resistance: Beyond the Androgen Paradigm,” was held at the University of California, Los Angeles...

PUBLISHED! Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025
PCF Coffey-Holden #ProstateCancer Academy Meeting!
Read up on all this exciting new research!
onlinelibrary.wiley.com/doi/10.1002/...

FDA approves niraparib and abiraterone acetate plus prednisone On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious B...

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive #ProstateCancer.
Thank you to all the clincians, researchers, and patients who made this new treatment option possible!
www.fda.gov/drugs/resour...

Prostate Cancer Grant: Deadline December 1, 2025! This grant was created in collaboration with the SNMMI Mars Shot Research Fund and Prostate Cancer Foundation for innovative research addressing unmet medical needs in the diagnosis and treatment of prostate cancer. This is a three-year grant and will provide $75,000 for three (3) years with travel expense to the PCF YI Meeting included. For full details and to submit your application, apply through the official grant portal.

APPLY: 2026 Young Investigator Award from SNMMI Mars Shot Research Fund & PCF for early career SNMMI members conducting innovative research addressing unmet medical needs in the diagnosis and treatment of #ProstateCancer.
@snmmi-marsshot.bsky.social

DEADLINE: Dec 1, 2025.
snmmi.org/MarsShot/

With all our work, immense gratitude goes to the patients and their families who participate in clinical trials. All the credit for this effort goes to my amazing team and collaborators who have not made taggable BlueSky accounts. The work was funded by @pcf-science.bsky.social, DOD and the NCI.

I'm pleased to share the latest paper from my lab, published online today at @jclinical-invest.bsky.social www.jci.org/articles/vie.... Patients with high risk prostate cancers that resist intense androgen derivation therapy harbor cancer cells that are sensitive to HER2 inhibitors. A "skytorial."

Big and well deserved congratulations to @zhipengawang.bsky.social for his new Prostate Cancer Foundation Young Investigator Award! So well deserved! He is doing incredible work discovering new mechanisms of ketones in metabolism. And congrats to all the other PCF young investigator awardees! 🧪

Honored to join the @pcf-science.bsky.social Young Investigator, Class of 2025. Excited to continue advancing #spatialprofiling of the #prostate #tumormicroenvironment to uncover new biomarkers and therapeutic strategies.

Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy | PNAS Prostate cancer is a global health challenge, particularly for patients resistant to the second-generation anti-androgen receptor pathway inhibitor...

Congrats Zhenfei Li and his team on his story @pnas.org on fine structural design of 3βHSD1 inhibitors for prostate cancer therapy! His work builds on many years of work on HSD3B1 genetics and metabolism in prostate cancer! @pcf-science.bsky.social 🧪https://www.pnas.org/doi/10.1073/pnas.2422267122

The 31st Annual Prostate Cancer Foundation Scientific Retreat Report Background The 31st Annual Prostate Cancer Foundation (PCF) Scientific Retreat took place in Carlsbad, CA on October 24–26, 2024. Methods The Annual PCF Scientific Retreat is the foremost internat...

PUBLISHED! The 31st Annual Prostate Cancer Foundation Scientific Retreat Report, which summarizes the cutting-edge research in #ProstateCancer & other fields presented at the 2024 @PCFnews
Retreat #PCFRetreat.

@andreamiyahira.bsky.social
onlinelibrary.wiley.com/doi/10.1002/...

Prostate Cancer Foundation 2025 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer REQUEST FOR LETTERS OF INTENT / FULL APPLICATIONS IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. TACTICAL Awards provide $5 - $10 Million U.S.D. per award over 3-5 years. • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of 3-5 years. • Institutional indirect costs of up to 10% will be allowed and should be included as part of the total research budget. • Clinical trial costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application.

ANNOUNCEMENT: RFA for 2025 PCF TACTICAL Award Letters Of Intent, for multi-institutional research projects to target lethal #ProstateCancer, in 6 specified topic areas.

LOI DEADLINE: May 19, 2025

View RFA: res.cloudinary.com/pcf/images/v...

View LOI form: res.cloudinary.com/pcf/images/v...

1/3 Big congrats to Justin Hwang, Emmanuel Antonarakis, @charlesryanmd.bsky.social & team on a story looking at germline HSD3B1 (which is linked to prostate cancer mortality) vs. tumor findings in prostate cancer! A couple of things that I find interesting here!🧪 www.mdpi.com/2072-6694/17...

Androgen receptor–regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer Long noncoding RNA PRCAT71 and RNA binding protein KHSRP stabilize androgen receptor mRNA to promote prostate cancer progression.

Thrilled to share our new study in
@ScienceAdvances
Androgen receptor–regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer | Science Advances www.science.org/doi/10.1126/... @pcf-science.bsky.social #lncRNA #ARsignaling #CancerResearch

Prostate Cancer Foundation 2025 PCF TACTICAL Awards Targeting Mechanisms of Lethal Prostate Cancer REQUEST FOR LETTERS OF INTENT / FULL APPLICATIONS IMPORTANT: Applying for a PCF TACTICAL Award (Therapy ACceleration To Intercept CAncer Lethality) involves a 3-stage process. PCF requires a Letter of Intent (LOI), followed by full application submission upon our invitation. Following peer review, top applicants will undergo a Zoom-based interview. The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. TACTICAL Awards provide $5 - $10 Million U.S.D. per award over 3-5 years. • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of 3-5 years. • Institutional indirect costs of up to 10% will be allowed and should be included as part of the total research budget. • Clinical trial costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application.

ANNOUNCEMENT: RFA for 2025 PCF TACTICAL Award Letters Of Intent, for multi-institutional research projects to target lethal #ProstateCancer, in 6 specified topic areas.

LOI DEADLINE: May 19, 2025

View RFA: res.cloudinary.com/pcf/images/v...

View LOI form: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2025 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below). • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. • Provide up to a total of $1 million per team. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application. • All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. Research proposals in the following topic areas are solicited: • Theranostics. • Drugging currently undruggable oncology targets: preventing progression to lethal disease. • Improved biotechnologies for precision medicine. • First-in-field immunotherapies for prostate cancer. • Artificial intelligence/machine learning to better inform patient outcomes. • Host microbiome and tumor metabolism.

ANNOUNCEMENT: RFA for 2025 @PCFnews team science Challenge Award Applications, to support investigations of metastatic, lethal #ProstateCancer in 6 specified topic areas.

DEADLINE: May 5, 2025

Apply at: pcf.smartsimple.com

View the RFA: res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation 2025 Young Investigator Awards REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers. Since 2007, PCF has awarded 429 PCF Young Investigator Awards in 16 countries, making it one of the most prodigious, productive, competitive and prestigious early career awards in cancer research. We are pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply. The mission of PCF is to fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer. PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.

ANNOUNCEMENT: RFA for 2025 @PCFnews Young Investigator Award Applications, to support innovative & highly promising early career #ProstateCancer researchers.

DEADLINE: March 10, 2025

Apply at: pcf.smartsimple.com

View the RFA here:
res.cloudinary.com/pcf/images/v...

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or...

Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples jamanetwork.com/journals/jam...

Grateful for the invitation to give a seminar March 4 at UCLA! Hope to see those there with any interest in prostate cancer, androgen physiology or steroid metabolism! Any chance to talk science these days is particularly therapeutic and a distraction from the distractions. @dgsomucla.bsky.social 🧪

NOW AVAILABLE: The 2024 State of Science Report, which summarizes the scientific presentations from the 2024 @PCFnews Annual Scientific Retreat! #PCFRetreat24

Download to learn about cutting-edge recent advances in #ProstateCancer research & treatment!
www.pcf.org/stateofscien...

Wonderful to have Scott Dehm from University of Minnesota visit Miami - always doing leading edge work in prostate cancer! @pcf-science.bsky.social

Prostate Cancer Foundation 2025 Young Investigator Awards REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (www.pcf.org) champions investment in human capital to fast-forward solutions for prostate cancer with the ultimate goal of ending death and suffering from metastatic prostate cancer. We continue to focus significant efforts on developing gifted cohorts of young prostate cancer researchers. Since 2007, PCF has awarded 429 PCF Young Investigator Awards in 16 countries, making it one of the most prodigious, productive, competitive and prestigious early career awards in cancer research. We are pleased to announce a new round of funding for PCF Young Investigators. We especially encourage young investigators working on prostate cancer health disparities to apply. The mission of PCF is to fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer. PCF Young Investigator Awards will be three (3) years in duration and will provide $75,000 per year. The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding “protected time” or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.

ANNOUNCEMENT: RFA for 2025 @PCFnews Young Investigator Award Applications, to support innovative & highly promising early career #ProstateCancer researchers.

DEADLINE: March 10, 2025

Apply at: pcf.smartsimple.com

View the RFA here:
res.cloudinary.com/pcf/images/v...

Prostate Cancer Foundation logo

PCF Science is now on BlueSky!
Follow us for prostate cancer research news & building the prostate cancer research community.